Literature DB >> 28486103

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.

Shany Koren1, Mohamed Bentires-Alj2.   

Abstract

Phosphoinositide-3-kinase (PI3K) pathway inhibitors have emerged as promising therapeutic agents for estrogen receptor (ERα)-positive breast cancers. However, incipient resistance limits the clinical benefit. Toska and colleagues identified that the epigenetic regulator KMT2D enhances ERα activity in BYL719-treated PIK3CA mutant breast cancer, leading to a rationale for targeting the epigenome and PI3K signaling.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28486103     DOI： 10.1016/j.ccell.2017.04.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

1.  Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells.

Authors:  John M Perry; Fang Tao; Anuradha Roy; Tara Lin; Xi C He; Shiyuan Chen; Xiuling Lu; Jacqelyn Nemechek; Linhao Ruan; Xiazhen Yu; Debra Dukes; Andrea Moran; Jennifer Pace; Kealan Schroeder; Meng Zhao; Aparna Venkatraman; Pengxu Qian; Zhenrui Li; Mark Hembree; Ariel Paulson; Zhiquan He; Dong Xu; Thanh-Huyen Tran; Prashant Deshmukh; Chi Thanh Nguyen; Rajeswari M Kasi; Robin Ryan; Melinda Broward; Sheng Ding; Erin Guest; Keith August; Alan S Gamis; Andrew Godwin; G Sitta Sittampalam; Scott J Weir; Linheng Li
Journal:  Nat Cell Biol       Date:  2020-04-20       Impact factor: 28.824

2.  DNA-mediated dimerization on a compact sequence signature controls enhancer engagement and regulation by FOXA1.

Authors:  Xuecong Wang; Yogesh Srivastava; Aleksander Jankowski; Vikas Malik; Yuanjie Wei; Ricardo Ch Del Rosario; Vlad Cojocaru; Shyam Prabhakar; Ralf Jauch
Journal:  Nucleic Acids Res       Date:  2018-06-20       Impact factor: 16.971

3.  Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma.

Authors:  Hui Xing; Mengshi Gao; Yuxiang Wang; Xu Zhang; Jiajie Shi; Xiang Wang; Xueling Liu; Qingyang Ma; Xiangyin Kong; Chunhao Yang; Jian Ding; Linghua Meng
Journal:  Clin Transl Med       Date:  2022-05

Review 4.  Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.

Authors:  Massimo Gadina; Nathalia Gazaniga; Laura Vian; Yasuko Furumoto
Journal:  J Autoimmun       Date:  2017-07-01       Impact factor: 7.094

5.  KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.

Authors:  Si-Si Li; Wei-Liang Jiang; Wen-Qin Xiao; Kai Li; Ye-Fei Zhang; Xing-Ya Guo; Yi-Qi Dai; Qiu-Yan Zhao; Ming-Jie Jiang; Zhan-Jun Lu; Rong Wan
Journal:  World J Gastrointest Oncol       Date:  2019-08-15

6.  KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.

Authors:  Qiaolian Li; Riping Wu; Fan Wu; Qiang Chen
Journal:  J Clin Lab Anal       Date:  2021-04-01       Impact factor: 2.352

7.  Dissecting the Kinetic Mechanism of Human Lysine Methyltransferase 2D and Its Interactions with the WRAD2 Complex.

Authors:  Lucy V Edwardes; Sarah J Caswell; Mariacarmela Giurrandino; Xiang Zhai; Andrea Gohlke; Demetrios H Kostomiris; Hannah K Pollard; Alexander Pflug; Gregory R Hamm; Kate V Jervis; Paul N Clarkson; Karl Syson
Journal:  Biochemistry       Date:  2022-09-07       Impact factor: 3.321

Review 8.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

9.  CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor.

Authors:  Cuixia Yang; Yumeng Sheng; Xiaoxing Shi; Yiwen Liu; Yiqing He; Yan Du; Guoliang Zhang; Feng Gao
Journal:  Cell Death Dis       Date:  2020-10-06       Impact factor: 8.469
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.